The team’s strategy—called antibody–ADC click—relies on the rapid ligation between trans‑cyclooctene (TCO) and tetrazine ...
Shares of AtaiBeckley (NASDAQ: ATAI) surged on Thursday after the mental health-focused biotechnology company agreed to be ...
Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage ...
17h
Google DeepMind Is Preparing For AI’s Biggest Risk. Biosecurity Is Becoming A New Battleground.
Google is expanding access to select AI tools for governments and researchers as scrutiny of biological risks associated with ...
NITI Aayog proposes a ₹50,000 crore fund to elevate India's biotech sector, targeting a $2.6 trillion bioeconomy by 2047.
Vir Biotechnology has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for ...
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
Prediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry ...
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its ...
A recovering IPO market, surging mergers and acquisitions fuel more biotech venture deals.
A NITI Aayog report outlines India's potential to scale its bioeconomy to USD 691 billion by 2035 and USD 2.6 trillion by ...
Growing interest in CIK cell therapy highlights challenges. Creative Biolabs supports researchers with CAR-CIK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results